GB1042194A - Insulin preparations - Google Patents

Insulin preparations

Info

Publication number
GB1042194A
GB1042194A GB14107/63A GB1410763A GB1042194A GB 1042194 A GB1042194 A GB 1042194A GB 14107/63 A GB14107/63 A GB 14107/63A GB 1410763 A GB1410763 A GB 1410763A GB 1042194 A GB1042194 A GB 1042194A
Authority
GB
United Kingdom
Prior art keywords
insulin
desalanino
desalamino
protamine
alkaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB14107/63A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olin Corp
Original Assignee
Olin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olin Corp filed Critical Olin Corp
Publication of GB1042194A publication Critical patent/GB1042194A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Desalanino insulin (i.e. insulin in which the C-terminal alanine groups have been removed) is prepared by treating an aqueous solution of insulin having an alkaline pH e.g. pH 7.8 with an aqueous solution of carboxypetidase having an alkaline pH e.g. pH 8.0, incubating 5 hours at 37 DEG C, and adjusting to pH 5.4 with hydrochloric acid to precipitate the desalamino insulin. The insulin may be derived from the pancreas of pigs, cattle, whales and fish. For injection, the insulin is dissolved in sterile water at pH 2 to 4, preferably buffered, and also containing sodium chloride and/or glycerin and a preservative such as phenol or m-cresol. The desalanino insulin may be used per se, as zinc desalanino insulin, protamine desalanino insulin, histone desalamino insulin, globin desalanino insulin or protamine &c. zinc desalanino insulin.
GB14107/63A 1962-04-30 1963-04-09 Insulin preparations Expired GB1042194A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19129362A 1962-04-30 1962-04-30

Publications (1)

Publication Number Publication Date
GB1042194A true GB1042194A (en) 1966-09-14

Family

ID=22704899

Family Applications (1)

Application Number Title Priority Date Filing Date
GB14107/63A Expired GB1042194A (en) 1962-04-30 1963-04-09 Insulin preparations

Country Status (2)

Country Link
FR (1) FR2800M (en)
GB (1) GB1042194A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011252127B2 (en) * 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
CN107029212A (en) * 2010-05-10 2017-08-11 诺沃—诺迪斯克有限公司 Method for preparing zinc insulin compound
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Also Published As

Publication number Publication date
FR2800M (en) 1964-09-21

Similar Documents

Publication Publication Date Title
DE69021335D1 (en) GROWTH HORMON FUSION PROTEINS.
Stolk et al. Brain norepinephrine: enhanced turnover after rubidium treatment
SE8101065L (en) ANTITROMBINBEREDNING
BR9814568A (en) "sexual insemination specifically of mammals with low number of sperm cells"
Valenta et al. Polymorphism of transferrin in carp (Cyprinus carpio L.): genetic determination, isolation, and partial characterization
GB1042194A (en) Insulin preparations
Matty et al. The production of exophthalmos by androgens in two species of teleost fish
De Vooys Formation and excretion of ammonia in teleostei: I. Excretion of ammonia through the gills
US3970749A (en) Interferon production
ES337291A1 (en) Process for the production of lysozyme
Smith et al. Toxicity of tritiated thymidine to bone marrow transplants
Jones et al. Rectal temperature and blood chemical responses of young chickens given E. coli endotoxin
Guba Observations on myosin and actomyosin
Moloney et al. NEUTRALIZATION OF COD INSULIN WITH ANTISERUM: PRECIPITATION OF INSULIN–ANTI-INSULIN COMPLEX WITH ETHANOL–WATER
Greenbaum et al. The effect of pituitary growth hormone and of insulin on the level of oxidized and reduced coenzyme I in the livers of normal and diabetic rats
Leone Ergothioneine in the equine ampullar secretion
ES359547A1 (en) Lupus erythematosus skin test
Hess et al. The Colorimetric Determination of Cystine in Tobacco Mosaic Virus Protein
FR2000070A1 (en) Pentafluorocinnamic acid anilides immunosuppressives
Jørgensen et al. Relative effectiveness of dehydration and neurohypophysial extracts in enhancing water absorption in toads and frogs
Pincus Qualitative tests on human enamel protein
FI60576B (en) FOERFARANDE FOER FRAMSTAELLNING AV LYSOZYM
GB1287674A (en) Injectable compositions
Swingle Iodine and anuran metamorphosis
Blaydes Preserving the natural color of green plants